neoag
Neoantigen × AI
Daily research signal
FIELD MAP / MODALITY

Dendritic-cell vaccines

Autologous dendritic cells loaded ex vivo with tumor neoantigens, then reinfused to prime a T-cell response.

Topic25 items2026-05-29 – 2026-07-15
Modalities
Peptide vaccines64TCR & T-cell receptor34mRNA vaccines31Dendritic-cell vaccines25Shared & off-the-shelf16DNA vaccines11Lipid nanoparticles5Viral-vector vaccines4Oncolytic viruses1
01
AI / Methods

A novel bivalent neoantigen vaccine based on mRNA-loaded lipid nanoparticles eradicates hepatocellular carcinoma in mice.

Researchers developed a bivalent mRNA-LNP vaccine targeting AFP and GPC3 neoantigens for hepatocellular carcinoma (HCC). Using spleen-homing CL15H6 LNPs, the formulation achieved superior antigen presentation and co-stimulatory molecule expression on splenic dendritic cells compared to clinical standards. In mouse models, two doses provided complete prophylactic protection against HCC challenge, demonstrating high biosafety and potent cytotoxic T lymphocyte responses.

mRNA vaccinesLipid nanoparticlesLiver cancer (HCC)
europepmc · brief 2026-07-15 · published 2026-07-13
03
Clinical

Personalized Neoantigen Dendritic Cell Vaccine in Glioblastoma - Bioengineer.org

Researchers Zhang, Chi, Liu, and colleagues published phase Ib results in Nature Communications for a personalized neoantigen-pulsed autologous dendritic cell therapy in newly diagnosed glioblastoma. The approach isolates patient dendritic cells, pulses them with tumor-specific neoantigens, and reintroduces them to activate cytotoxic T-cells against the heterogeneous tumor. This represents a direct clinical validation of personalized DC vaccine strategies for an aggressive brain cancer with limited treatment options.

Glioblastoma
news · brief 2026-07-04 · published 2026-07-04
04
Clinical

Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma

Beijing YSCell Biotech is launching an investigator-initiated, open-label Phase 1 trial for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection for recurrent or progressive glioblastoma. The study employs a '3+3' dose-escalation design across three cohorts to assess safety, tolerability, and preliminary efficacy. Patients will receive subcutaneous injections every two weeks for eight doses.

Glioblastoma
clinicaltrials · brief 2026-07-01 · published 2026-07-01
05
Clinical

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

David Avigan is leading a Phase 1 study of a DC/Multiple Myeloma fusion vaccine combined with the T-cell engager elranatamab in relapsed/refractory multiple myeloma. This trial tests the safety and efficacy of pairing a personalized cellular vaccine with bispecific antibody technology.

clinicaltrials · brief 2026-06-16 · published 2026-05-07
13
Clinical

Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma

ZSky Biotech Inc is preparing a multicenter, open-label, randomized Phase II study for newly diagnosed glioblastoma. The trial compares the efficacy and safety of ZSNeo-DC1.1, a personalized dendritic cell vaccine, combined with temozolomide against temozolomide alone, with progression-free survival as the primary endpoint.

Glioblastoma
clinicaltrials · brief 2026-06-13 · published 2026-01-26
16
Clinical

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

Peking University Third Hospital is preparing a not-yet-recruiting dose-escalation study for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection. The trial will evaluate safety, tolerability, and preliminary efficacy in participants with HRD-negative epithelial ovarian cancer.

Ovarian cancer
clinicaltrials · brief 2026-06-08 · published 2026-03-16
18
Clinical

Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery

Beijing Tiantan Hospital completed a Phase I study evaluating autologous dendritic cells loaded with tumor neoantigen peptides alongside temozolomide in newly diagnosed glioblastoma. The trial focused on safety and preliminary efficacy, contributing data on DC-based vaccine platforms in this indication.

Peptide vaccinesGlioblastoma
clinicaltrials · brief 2026-06-02 · published 2026-05-04
20
Clinical

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

Fudan University is conducting a clinical study of a personalized self-dendritic cell (self-DC) vaccine targeting neoantigens for advanced solid tumors. The trial focuses on the application of autologous dendritic cells loaded with patient-specific neoantigens, representing a distinct delivery platform within the personalized vaccine landscape.

clinicaltrials · brief 2026-05-30 · published 2026-04-02
22
Clinical

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

Jonsson Comprehensive Cancer Center is running a Phase I trial for a neoantigen-targeted peptide-pulsed dendritic cell (ppDC) vaccine in patients with H3 G34-mutant diffuse hemispheric glioma. The active, non-recruiting study focuses on identifying the best dose and safety profile of this patient-specific immunotherapy.

Peptide vaccinesGlioblastoma
clinicaltrials · brief 2026-05-30 · published 2026-02-17
23
Clinical

Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma

ZSky Biotech Inc is conducting a multicenter, randomized Phase II study of ZSNeo-DC1.1, a personalized dendritic cell vaccine, combined with temozolomide for newly diagnosed glioblastoma. The trial’s primary endpoint is progression-free survival (PFS) per RANO 2.0 criteria, with exploratory objectives assessing antigen-specific T-cell responses.

Glioblastoma
clinicaltrials · brief 2026-05-30 · published 2026-01-26
25
AI / Methods

Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances.

A comprehensive review in EuropePMC synthesizes the current state of neoantigen-based T cell vaccines, covering design strategies, therapeutic barriers, and clinical advances. The article examines mechanisms across mRNA, peptide, and dendritic cell platforms, highlighting synergies with checkpoint blockade and the challenges of immunosuppressive tumor microenvironments.

mRNA vaccinesPeptide vaccines
europepmc · brief 2026-05-29 · published 2026-05-01
Where nextAll topicsToday’s briefTrials tracker